Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT).
Oral mucositis (OM) is a frequent complication of myeloablative therapy and HSCT. We evaluated the feasibility, reliability, and validity of a new patient self-reported daily questionnaire on OM and its impact on daily functions. This OM Daily Questionnaire (OMDQ), containing 10 items, was developed for use in palifermin clinical trials. In a phase 3 study, 212 patients received palifermin or placebo for three consecutive days before conditioning and three consecutive days after HSCT. Compliance rates were consistently >80% for most patients. Mouth and throat soreness (MTS) and MTS-Activity Limitations (MTS-AL) (swallowing, drinking, eating, talking, and sleeping) scores on consecutive days were highly correlated (days 7,8 = 0.70-0.86; test-retest reliability). Correlations among items measuring the same construct ranged between 0.5 and 0.8 (internal consistency reliability). The WHO Oral Toxicity scale was the clinical comparator to assess the criterion, discriminative, and evaluative validities of MTS-related questions. Most correlation coefficients between the WHO and MTS ranged between 0.45 and 0.55. Patients with more severe WHO OM grades had higher MTS mean scores. Changes in MTS scores were similar, but patients detected changes 1-3 days earlier than clinicians. In conclusion, the OMDQ is a feasible, reliable, valid, and responsive patient-reported measure of OM severity.
Stiff
P J
PJ
Cardinal Bernardin Cancer Center, Loyola University, Maywood, IL 60153, USA. pstiff@lumc.edu
Erder
H
H
Bensinger
W I
WI
Emmanouilides
C
C
Gentile
T
T
Isitt
J
J
Lu
Z J
ZJ
Spielberger
R
R
D000203:Activities of Daily Living; D000293:Adolescent; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005240:Feasibility Studies; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000175:diagnosis* / Q000209:etiology; D010349:Patient Compliance; D010919:Placebos; D015203:Reproducibility of Results; D013280:Stomatitis / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D011795:Surveys and Questionnaires; D014182:Transplantation, Autologous
D010919:Placebos; D051523:Fibroblast Growth Factor 7